Aides launches awareness campaign on the Prep

"PrEp: one tablet a day protects you from HIV". This is the catch of this first campaign # Prep4Love, at the initiative of the badociation to fight the AIDS virus Aides. It will be visible on display all summer in the largest cities of France, the press and on the web and networks. Visuals will represent heterobadual couples as homobaduals.

The PrEp – of "Pre" before, "Exposure" contact with HIV and "Prophylaxis" prevention of infection – is a tool intended to bring down the number new infections with HIV. It complements other means of prevention such as the condom, the treatment of HIV-positive people or screening.

Touching women and migrant people

The PrEp "punishment yet to reach its targets, "notes the badociation: 18 months after its marketing authorization, only 7,000 people in France use this preventive treatment, Truvada and its generics.

It is still largely unknown, especially women who are at risk of AIDS. According to the latest available data, 97% of Prep prescriptions concern MSM (men who have bad with men). And women "represent only 1% of inclusions" in this prevention program, the badociation points out.

While women are particularly vulnerable. " This tool is for people who are most exposed to the AIDS virus, especially those who find it difficult to use a condom or negotiate its use with their partners. all too often dependent on the willingness of men to protect themselves against HIV " explains Camille Spire, a member of AIDES 'board of directors

Migrants from sub-Saharan Africa, who are also very concerned about HIV HIV, remain uninformed about this preventive treatment, adds Aides.

All adults at risk

According to the High Authority of Health (HAS), PrEP is recommended for all adults at high risk of acquiring HIV. These include homobaduals or MSM, especially if they have had an STI / STI or HIV treatment after a risky relationship in the past year, and prostitutes who have unprotected bad.

In a brochure on the proper use of this preventive treatment, intended for health professionals and put online in May by the ANSM drug agency, it is stated that from now on "the information provided in this document concerns the adult and adolescent ".